{"disease":{"id":"relapsed-and-refractory-peripheral-t-cell-lymphoma","name":"relapsed and refractory peripheral t cell lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05527275","title":"A Phase I/II Study of Mitoxantrone Liposome Combined With Chidamide in Relapsed/Refractory Peripheral T-cell Lymphoma","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":78,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07055477","title":"A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}